Syndrome, a type of obesity characterized by increased facial and abdominal fat. This is also associated with increased risk for; heart disease, stroke, hypertension, cancer and diabetes. All these conditions are associated with stress related elevated cortisol levels. The new findings with Relora are very exciting because Relora is the first Relora is a new patent pending plant extract of Phellodendron amurense and Magnolia officinalis that may help relieve stress and anxiety and minimize stress-induced eating. The plant extracts in Relora bind to important target receptors in the central nervous system that are associated with anxiety. Relora does not bind with the receptors that cause sedation, yet has the relaxing qualities that some of the benzodiazepine drugs have, without the drowsiness.

Chronic stress has been shown to be a contributing factor in compulsive food cravings which can lead to obesity. Relora is a safe non-sedating formula that can help to alleviate symptoms associated with stress. Preliminary research has shown that Relora may help to regulate cortisol production in the body. High levels of cortisol have been shown to be associated with emotional over-eating in people who suffer with stressful lives.

Next Pharmaceuticals developed Relora over a three-year period of screening fractions of various plants from around the world, running human trials, and conducting pharmacology and toxicology studies. These studies showed that eight out of ten stressed individuals felt more relaxed, and seven out of ten enjoyed a more restful sleep after taking Relora. Nine out of ten said that it was gentle on the stomach.

More than 20 percent of North American adults have Metabolic Syndrome, a type of obesity characterized by increased facial and abdominal fat. This is also associated with increased risk for; heart disease, stroke, hypertension, cancer and diabetes. All these conditions are associated with stress related elevated cortisol levels. The new findings with Relora are very exciting because Relora is the first n

cause sedation, yet has the relaxing qualities that some of the benzodiazepine drugs have, without the drowsiness.

Chronic stress has been shown to be a contributing factor in compulsive food cravings which can lead to obesity. Relora is a safe non-sedating formula that can help to alleviate symptoms associated with stress. Preliminary research has shown that Relora may help to regulate cortisol production in the body. High levels of cortisol have been shown to be associated with emotional over-eating in people who suffer with stressful lives.

Next Pharmaceuticals developed Relora over a three-year period of screening fractions of various plants from around the world, running human trials, and conducting pharmacology and toxicology studies. These studies showed that eight out of ten stressed individuals felt more relaxed, and seven out of ten enjoyed a more restful sleep after taking Relora. Nine out of ten said that it was gentle on the stomach.

More than 20 percent of North American adults have Metabolic Syndrome, a type of obesity characterized by increased facial and abdominal fat. This is also associated with increased risk for; heart disease, stroke, hypertension, cancer and diabetes. All these conditions are associated with stress related elevated cortisol levels. The new findings with Relora are very exciting because Relora is the first

search has shown that Relora may help to regulate cortisol production in the body. High levels of cortisol have been shown to be associated with emotional over-eating in people who suffer with stressful lives.

Next Pharmaceuticals developed Relora over a three-year period of screening fractions of various plants from around the world, running human trials, and conducting pharmacology and toxicology studies. These studies showed that eight out of ten stressed individuals felt more relaxed, and seven out of ten enjoyed a more restful sleep after taking Relora. Nine out of ten said that it was gentle on the stomach.

More than 20 percent of North American adults have Metabolic Syndrome, a type of obesity characterized by increased facial and abdominal fat. This is also associated with increased risk for; heart disease, stroke, hypertension, cancer and diabetes. All these conditions are associated with stress related elevated cortisol levels. The new findings with Relora are very exciting because Relora is the first

ing human trials, and conducting pharmacology and toxicology studies. These studies showed that eight out of ten stressed individuals felt more relaxed, and seven out of ten enjoyed a more restful sleep after taking Relora. Nine out of ten said that it was gentle on the stomach.

More than 20 percent of North American adults have Metabolic Syndrome, a type of obesity characterized by increased facial and abdominal fat. This is also associated with increased risk for; heart disease, stroke, hypertension, cancer and diabetes. All these conditions are associated with stress related elevated cortisol levels. The new findings with Relora are very exciting because Relora is the first

Syndrome, a type of obesity characterized by increased facial and abdominal fat. This is also associated with increased risk for; heart disease, stroke, hypertension, cancer and diabetes. All these conditions are associated with stress related elevated cortisol levels. The new findings with Relora are very exciting because Relora is the first natural product for lowering cortisol and decreasing stress, which has been shown to cause the excess fat deposits seen in Metabolic Syndrome.

Relora has been shown to: help to relieve stress, reduce anxiety, help control irritability, depression, improve blood flow, and hormonal balance. Some precautions when taking Relora: keep out of the reach of children, do not take with alcoholic beverages, excessive consumption may impair driving ability. If you are pregnant or are breast feeding, or if you are taking any other medication, you should consult your physician before taking Relora.